PrEP: Roadblocks to implementation

Similar documents
Condoms, PrEP, and the use of ART to prevent the sexual transmission of HIV: Overview of the science and recommendations for service providers

Pre-exposure prophylaxis (PrEP)

HIV Pre-Exposure Prophylaxis (PrEP): A brief guide for providers updated January 2016

HPTN 073: Black MSM Open-Label PrEP Demonstration Project

Providing Optimal Care for Your MSM Patients

PEER REVIEW HISTORY ARTICLE DETAILS TITLE (PROVISIONAL)

Frequently Asked Questions: Pre-Exposure Prophylaxis (PrEP) for HIV Infection Massachusetts Department of Public Health Updated July 2013

Frequently Asked Questions (FAQs)

Clinical Infectious Diseases Advance Access published September 1, 2015

Getting to Know PrEP (Pre-Exposure Prophylaxis)

Transcending Barriers for Safer Pleasure

HIV/AIDS Prevention and Care

Routine HIV Monitoring

NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS (npep)

HIV (Human Immunodeficiency Virus) Screening and Pre-Exposure Prophylaxis Guideline

A publication for men who have sex with men. Is taking PrEP the right choice for you? your life matters

PEER REVIEW HISTORY ARTICLE DETAILS TITLE (PROVISIONAL)

Scaling Up Pre-Exposure Prophylaxis in California

Incorporating PrEP into Comprehensive HIV Prevention Programs

NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS FOR SEXUAL ASSAULT SURVIVORS. Carl LeBuhn, MD

Stefan R. Rowniak, PhD, RN, MS, FNP. University of California, San Francisco, CA. University of California, San Francisco, CA

The Role of New Media on Sexual Health

Special Considerations

Q and A for PARTNER Studies: Interim analysis results presented at CROI CROI presentation can be found at

TOOLS, TRENDS AND NEW TECHNOLOGIES IN HIV PREVENTION

DC Comprehensive HIV Prevention Plan for : Goals and Objectives

Injection Drug Users in Miami-Dade: NHBS-IDU2 Cycle Preliminary Results

Response to HIV/AIDS in Brazil, public health system strengthening and programmatic integration

FAQs HIV & AIDS. What is HIV? A virus that reduces the effectiveness of your immune system, meaning you are less protected against disease.

The Basics of Drug Resistance:

HIV prevention and the wider UK population. What HIV prevention work should be directed towards the general population in the UK?

Aim of Presentation. The Role of the Nurse in HIV Care. Global Epidemic 7/24/09

POST-EXPOSURE PROPHYLAXIS IN THE HEALTH CARE SETTING

Exposure. What Healthcare Personnel Need to Know

SPECIALTY PROVIDER MANUAL

The use of ARVs in HIV prevention and the case for optimizing the preventive impact of ART?

ALAMEDA COUNTY, CALIFORNIA COMPREHENSIVE HIV PREVENTION PLAN

HIV Prevention Action Coalition (A Workgroup of the Federal AIDS Policy Partnership) Gay Men s Subgroup

Aids Fonds funding for programmes to prevent HIV drug resistance

POST-EXPOSURE PROPHYLAXIS (HIV, HEP B, HEP C)

The Value of Innovation in HIV/AIDS Therapy

Health Issues Affecting Older Gay, Lesbian and Bisexual People in the UK

Teenage Pregnancy and Sexual Health Marketing Strategy November 2009

MILITARY HEALTHCARE PROVIDER KNOWLEDGE AND COMFORT REGARDING THE MEDICAL CARE OF ACTIVE DUTY LESBIAN, GAY, AND BISEXUAL PATIENTS

Outpatient/Ambulatory Health Services

Ending the Epidemic in New York State. Federal AIDS Policy Partnership March 4, 2015

guidance note 2012 KEY PROGRAMMES TO REDUCE STIGMA AND DISCRIMINATION AND INCREASE ACCESS TO JUSTICE IN NATIONAL HIV RESPONSES

AAB 2013 Annual Meeting & Educational Conference

HIV New Diagnoses, Treatment and Care in the UK 2015 report

Perspective Implications of the Affordable Care Act for People With HIV Infection and the Ryan White HIV/AIDS Program: What Does the Future Hold?

UPDATE UNAIDS 2016 DATE 2016

HIV treatment for overseas visitors

Australian Federation of AIDS Organisations (AFAO) Primary Health Care Reform

Building on Success: A National Strategy to Save Lives


Effective Integration of STI & HIV Prevention Programs

Didactic Series. Updated Post-Exposure Prophylaxis (PEP) Guidelines. Daniel Lee, MD UCSD Medical Center, Owen Clinic January 9, 2014

Targeted HIV Testing & Enhanced Testing Technologies. HIV Prevention Section Bureau of HIV/AIDS

Chlamydia THE FACTS. How do people get Chlamydia?

PREEXPOSURE PROPHYLAXIS FOR THE PREVENTION OF HIV INFECTION IN THE UNITED STATES 2014

Department of Veterans Affairs National HIV/AIDS Strategy Operational Plan 2011

Dublin Declaration. on Partnership to fight HIV/AIDS in Europe and Central Asia

Condoms for the prevention of HIV and STI transmission

Rapid Assessment of Sexual and Reproductive Health

HIV/AIDS AND OTHER SEXUALLY TRANSMITTED INFECTIONS 11


NATIONAL HIV/AIDS STRATEGY for the UNITED STATES: UPDATED TO 2020

PLUS MAY EQUAL. Flu-Like Symptoms SORE THROAT, SWOLLEN GLANDS, FEVER, JOINT AND MUSCLE ACHES

disabilities THE GAP REPORT 2014

The Impact of the ACA and USPSTF Grade Change on Coverage of HIV Testing

HIV/AIDS AND HOMELESSNESS Evelyn P. Tomaszewski, MSW Senior Policy Associate

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention

Science addressing drugs and HIV: State of the Art. Vienna

Prevention of transmission of HIV and other bloodborne viruses in healthcare and post exposure prophylaxis. John Ferguson, UPNG 2012

24 th Meeting of the UNAIDS Programme Coordinating Board Geneva, Switzerland June 2009

A Ministry of the Archdiocese of Galveston-Houston A United Way Agency

Figure 2. Estimated Number of People Living with HIV/AIDS (PLWHA) in LAC, Unaware HIV/AIDS (1) Pending HIV Cases (2) Coded Living HIV

Patient Educational Strategies

Rapid Assessment of Sexual and Reproductive Health

The HIV/AIDS Epidemic in California s Latino Population

HIV Prevention Needs Assessment for London

Using Substance Abuse Prevention and Treatment (SAPT) Block Grant HIV Set- Aside Funds for Integrated Services

Preventive Care Guideline for Asymptomatic Low Risk Adults Age 18 through 64

Empowering and Promoting HIV Leaders in MSM of Color Communities

UNITED NATIONS GENERAL ASSEMBLY SPECIAL SESSION ON HIV/AIDS. Country Progress Report Sweden

HIV Surveillance Update

Estimates of New HIV Infections in the United States

UNAIDS 2014 LESOTHO HIV EPIDEMIC PROFILE

HIV/AIDS, Socioeconomic Status, and Life Insurance. The burden of being infected with the life-threatening disease HIV/AIDS

THIS IS AN OFFICIAL NH DHHS HEALTH ALERT

State Adolescent Consent Laws and Implications for HIV Pre-Exposure

Epidemiology of Hepatitis C Infection. Pablo Barreiro Service of Infectious Diseases Hospital Carlos III, Madrid

THT BRIGHTON HEALTH PROMOTION: UTILISING ONLINE, MOBILE APPS & SOCIAL MEDIA

HIV& AIDS BASIC FACTS. HIV & Drug Use. You are better off knowing if you have HIV. HIV & Sex. What are HIV & AIDS? HIV & Blood Products

Using HIV Surveillance Data to Calculate Measures for the Continuum of HIV Care

Limits and Complexity: Research on Stigma and HIV Laurel Sprague, Ph.D., The Sero Project. Photo Credits to European AIDS Treatment Group

Moving Toward Reduced HIV Incidence: How the San Francisco Experience Can Inform National HIV/AIDS Strategy Implementation

UNAIDS ISSUES BRIEF 2011 A NEW INVESTMENT FRAMEWORK FOR THE GLOBAL HIV RESPONSE

HIV and AIDS in Bangladesh

Gay and Lesbian Activists Alliance of Washington, DC 2015 Questionnaire for D.C. Council Candidates. Brandon Todd, Democrat, Ward 4 Council Candidate

Transcription:

1 Què és el VIH i què és la sida? PrEP: Roadblocks to implementation Pep Coll pcoll@irsicaixa.es 14th European Meeting on HIV & Hepatitis 2016 AIDS Research Institute

Disclosures és el VIH i què és la sida? Research grant: Gilead Advisory Boards : Gilead, ViiV

Agenda és el VIH i què és la sida? Background Roadblocks Challenges

What és el VIH about i què és la sida? Europe?

Background és el VIH i què és la sida? PrEP works!!!

Background és el VIH i què és la sida?

PrEP és el VIH works i què és la sida? if it s taken Adherence is crucial But high protection even with adherence not 100% in MSM and transgender women iprex OLE study Grant R et al. CROI 2014

What és el VIH about i què és la sida? Europe? PROUD study in UK Ipergay study in France and Canada

What és el VIH about i què és la sida? Europe?

What és el VIH about i què és la sida? Europe?

What és el VIH about i què és la sida? Europe?

What és el VIH about i què és la sida? Europe?

What és el VIH about i què és la sida? in real world? Kaiser Permanente study 657 MSM San Francisco 32 months follow-up NO NEW HIV INFECTIONS Volk JE et al. No New HIV Infections With Increasing Use of HIV Preexposure Prophylaxis in a Clinical Practice Setting. Clin Infect Dis. 2015 Nov 15;61(10):1601-3. doi: 10.1093/cid/civ778.

What és el VIH about i què és la sida? in real life? Ongoing demonstration projects: Amsterdam Antwerp Bologna Spain?

Where és el VIH i què is és PrEP la sida? available in Europe? France 60 PrEP clinics Fully covered by the national health insurance Available since January 2016 Provided through a Recommendation of Temporary Use (RTU) http://www.aides.org/info-sante/prep

Where és el VIH i què is és PrEP la sida? available in Europe? Jean-Michel Molina

Where és el VIH i què is és PrEP la sida? available in Europe? UK PROUD study finished by April 2016 NHS: prevention is remit of local health authorities

1 Què és el VIH i què és la sida?

Where és el VIH i què is és PrEP la sida? available in Europe? PROUD designed to mimic real-world Until April 2016 NHS not responsible for prevention but local authorities

Where és el VIH i què is és PrEP la sida? available in Europe?

Where és el VIH i què is és PrEP la sida? available in Europe? Demonstration projects Amsterdam Antwerp Spain?

14 Què és el VIH i què és la sida? What are we waiting for?

Roadblocks és el VIH i què és la sida? Indication of Truvada for PrEP not yet approved by the European Medicines Agency Submitted in January 2016 Approved by FDA in July 2012

Roadblocks és el VIH i què és la sida? Knowledge and beliefs about PrEP among health professionals

New England prescribers perceived numerous barriers to prescribing PrEP Clinician perceived barriers to prescribing PrEP (N = 155) Time constraints (eg, to discuss PrEP, counselling/monitoring) Concerns about whether insurers will cover the cost of PrEP Lack of pt request for PrEP 22 38 31 9 10 26 31 32 7 22 45 26 Limited number of high-risk, HIV-uninfected pts Clinicians not aware of guidance from normative bodies (eg, CDC) 27 33 25 15 19 22 33 25 Clinicians not trained to prescribe PrEP 14 22 30 35 Not a barrier Minor barrier Moderate barrier Major barrier Clinicians not aware of PrEP 23 27 31 20 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Krakower DS, et al. PLoS One. 2015;10:e0132398.

Roadblocks és el VIH i què és la sida? 43 % who had not prescribed PrEP did not envision doing so in the future 26 % were unfamiliar with CDC guidance on PrEP (more than 2 years after publication) Most concerned about side effects, drug resistances or increased risk behaviour Krakover et al. Knowledge, Beliefs and Practices Regarding Antiretroviral Medications for HIV Prevention: Results from a Survey of Healthcare Providers in New England PLoS One. 2015;10(7):e0132398.

Roadblocks és el VIH i què és la sida? Community Lack of information Survey among MSM in Rhode Island (N = 178) 71 % had little or no information about PrEP Merchant et al. Preferences for HIV pre-exposure prophylaxis (PrEP) information among menwho-have-sex-with-men (MSM) at community outreach settings. J Gay Lesbian Ment Health. 2016 ; 20(1): 21 33. doi:10.1080/19359705.2015.1105115.

Roadblocks és el VIH i què és la sida? Stigma and lack of community acceptance of PrEP Adherence may be compromised in situations where there is a need to conceal PrEP use Haire BG. Preexposure prophylaxis-related stigma: strategies to improve uptake and adherence a narrative review. HIV/AIDS - Research and Palliative Care.2015;7:241-249. Participants reported that they were unlikely to disclose PrEP use to family due to fear of rejection or being seen as promiscuous Galea et al. Acceptability of pre-exposure prophylaxis as an HIV prevention strategy: barriers and facilitators to pre-exposure prophylaxis uptake among at-risk Peruvian populations. Int J STD AIDS. 2011;22(5):256 262.

Roadblocks és el VIH i què és la sida? Concerns, fears & misconceptions Toxicity % Adverse Events similar in PrEP and placebo groups Small decrease in renal function and bone mineral density (often not progressing or reversible)

Roadblocks és el VIH i què és la sida? Concerns, fears & misconceptions Drug resistances Low risk of resistance to tenofovir or FTC during use of PrEP Higher risk among those acutely HIV-infected when starting PrEP How implementing PrEP on large scale affects resistance overall is unknown

Roadblocks és el VIH i què és la sida? Concerns, fears & misconceptions Risk compensation No differences in condom use, number of sexual partners and STI incidence Increased in IAVI Kenia study San Francisco study: high STI incidence and a 41 % decrease in reported condom use among a sub-set of PrEP users Regular STI screening

Roadblocks és el VIH i què és la sida? Concerns, fears & misconceptions Cost Cost-effectivity analysis Offering PrEP is expected to be cost-effective where the incidence of HIV is greater than 3 per 100 person-years and perhaps also at lower incidence

Challenges és el VIH i què és la sida? Address skepticism from clinicians, gay community, payers and general population Increase PrEP awareness among health professionals and people at risk Adapt prevention messages to include PrEP

Challenges és el VIH i què és la sida? Define appropriate models of care and access points (hospitals, sexual health clinics, primary care, community-based organizations) Monitor and evaluate PrEP implementation New formulas (vg long acting drugs) Reduce cost of drugs for PrEP

Challenges és el VIH i què és la sida? Address remaining skepticism from physicians, the Gay community, the payers and the general population Increase PrEP awareness among clinicians and people at risk SAN FRANCISCO AIDS FOUNDATION Provide information about how well PrEP works Build community support for PrEP

14 Què és el VIH i què és la sida? What are we waiting for?